Z
Zumutor Biologics
Better health through better biologics
About Zumutor Biologics
Zumutor Biologics Inc., founded in 2015 and headquartered in Woburn, MA, USA, is a pioneering company in the field of Immuno-Oncology, specializing in targeted Natural Killer (NK) cell therapeutics. The company operates in the biotechnology sector, focusing on developing novel immunotherapies and monoclonal antibodies to regulate the tumor microenvironment and enhance innate immunity. Zumutor's proprietary Human Antibody platform, INABLR, is the foundation for its first-in-class therapeutic antibodies, which aim to treat multiple solid cancers. The company serves pharmaceutical and biotechnology clients, leveraging its high-diversity human antibody libraries to identify and develop innovative treatments. Zumutor generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary therapies. The company has an ISO 9001:2008 certified laboratory in Bangalore, India, and has attracted significant investment from global advisors and investors.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Woburn, United States
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Zumutor Biologics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Accel
IDG Ventures
Aarin Capital
Bharat Innovation Fund
Series A3 investors entered at this stage
Siana Capital Management
Premji Invest- AKAshish Kacholia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zumutor Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zumutor Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.